|
|
 Previous Article | Table of Contents | Next Article 
High serum and ascitic soluble interleukin-2 receptor alpha levels in
advanced epithelial ovarian cancer [see comments]
DP Barton, DK Blanchard, B Michelini-Norris, SV Nicosia, D Cavanagh and JY Djeu
Immunology Program, H. Lee Moffitt Cancer Center and Research Institute,
Tampa, FL 33612.
This study was undertaken to determine if advanced epithelial ovarian
cancer was associated with increased serum and ascitic levels of soluble
interleukin-2 receptor alpha (sIL-2R alpha). Serum and ascitic fluid
samples from 23 ovarian cancer patients were analyzed for sIL-2R alpha
using an enzyme-linked immunosorbent assay and compared with the serum and
peritoneal levels in 18 normal females. The samples were analyzed for
CA-125 levels using a radioimmunoassay and the total protein was also
measured. Normal individuals had low serum levels of sIL-2R alpha (367.5
+/- 44.6 U/mL), with similar levels of sIL-2R alpha in the normal
peritoneal fluid (438.6 +/- 48.8 U/mL). In contrast, the serum and ascitic
fluid levels in ovarian cancer patients were significantly higher (746.7
+/- 82.9 U/mL, P = .0006; 2,656.7 +/- 373.7 U/mL, P = .00002,
respectively). The results for sIL-2R alpha were also significant when the
levels were expressed per milligram of total protein. More importantly, in
almost every ovarian cancer patient the ascitic sIL-2R alpha level far
exceeded the serum level, a pattern also observed for CA-125. There was no
correlation between the serum and ascitic sIL-2R alpha levels, or between
the serum and ascitic CA-125 levels. Although the serum levels of sIL-2R
alpha and CA-125 were elevated in the same patient, overall there was no
correlation between the serum sIL-2R alpha and serum CA-125 levels, either
when the levels were expressed in absolute units or per milligram of total
protein. Similarly, there was no correlation between sIL-2R alpha and
CA-125 levels in individual ascitic samples. While CA-125 levels may
reflect an independent index of tumor burden, these results suggest that
selective accumulation of sIL-2R alpha in the ascites may be one of the
factors associated with the known nonresponsiveness of the infiltrating
lymphocytes against ovarian carcinoma cells.
Volume 81,
Issue 2,
pp. 424-429,
01/15/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. F. Skinnider and T. W. Mak
The role of cytokines in classical Hodgkin lymphoma
Blood,
May 29, 2002;
99(12):
4283 - 4297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Akin, L. B. Schwartz, T. Kitoh, H. Obayashi, A. S. Worobec, L. M. Scott, and D. D. Metcalfe
Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology
Blood,
August 15, 2000;
96(4):
1267 - 1273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L.-S. Wang, K.-C. Chow, W.-Y. Li, C.-C. Liu, Y.-C. Wu, and M.-H. Huang
Clinical Significance of Serum Soluble Interleukin 2 Receptor-{{alpha}} in Esophageal Squamous Cell Carcinoma
Clin. Cancer Res.,
April 1, 2000;
6(4):
1445 - 1451.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H. Iwasaki, K. Shimoda, S. Okamura, T. Otsuka, K. Nagafuji, N. Harada, Y. Ohno, T. Miyamoto, K. Akashi, M. Harada, et al.
Production of Soluble Granulocyte Colony-Stimulating Factor Receptors from Myelomonocytic Cells
J. Immunol.,
December 15, 1999;
163(12):
6907 - 6911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. J. Barton, D. K. Blanchard, C. Duan, W. S. Roberts, D. Cavanagh, S. DeCesare, and J. Y. Djeu
Interleukin-12 Synergizes With Interleukin-2 to Generate Lymphokine-Activated Killer Activity in Peripheral Blood Mononuclear Cells Cultured in Ovarian Cancer Ascitic Fluid
Reproductive Sciences,
November 1, 1995;
2(6):
762 - 771.
[Abstract]
[PDF]
|
|
|
|
|
